Insulin Resistance and T2D Associated With Gut Microbial Diversity
By LabMedica International staff writers Posted on 13 Aug 2021 |
The MiSeqDx System is the first FDA-regulated, CE-IVD-marked, NGS platform for in vitro diagnostic (IVD) testing (Photo courtesy of Illumina)
Type 2 diabetes (T2D) is a common complex metabolic disorder. Currently, more than 380 million people live with type 2 diabetes globally, and this number is expected to increase to more than 550 million by 2030.
Differences in gut microbiome composition with T2D status may comprise pathways on how dietary and other environmental factors affect development of insulin resistance and T2D. Patients with T2D have a lower overall α diversity of gut microbiome composition than healthy people.
A multidisciplinary international team of scientists led by those at the Erasmus University Medical Center (Rotterdam, the Netherlands) examined associations of gut microbiome composition with insulin resistance and T2D in a large population-based setting controlling for various sociodemographic and lifestyle factors. The team carried out a cross-sectional analysis included 2,166 participants from two Dutch population-based prospective cohorts.
The investigators used an automated stool DNA isolation kit (Diasorin, Saluggia, Italy) to isolate bacterial DNA. The V3 and V4 hypervariable regions of the bacterial 16S ribosomal RNA gene were amplified and sequenced on the MiSeq platform (Illumina, San Diego, CA, USA). Serum insulin was measured by electrochemiluminescence immunoassay technology. In one study, glucose levels were measured by hydrogen 1 nuclear magnetic resonance, and serum insulin was measured on an architect system (Abbott Laboratories, Lake Forest, IL, USA). Associations among α diversity, β diversity, and taxa with the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and with type 2 diabetes were examined.
The investigators reported that lower microbiome Shannon index and richness were associated with higher HOMA-IR (e.g., Shannon index, −0.06; 95% CI, −0.10 to −0.02), and patients with type 2 diabetes had a lower richness than participants without diabetes (odds ratio [OR], 0.93; 95% CI, 0.88-0.99). The β diversity)was associated with insulin resistance. A total of 12 groups of bacteria were associated with HOMA-IR or type 2 diabetes. There were five taxa whose higher abundance was tied to lower prevalence of T2D:Clostridiaceae 1, Peptostreptococcaceae, Clostridium sensu stricto 1, Intestinibacter, and Romboutsia. There were seven taxa whose greater abundance was associated with lower HOMA-IR including Christensenellaceae and Marvinbryantia.
The authors concluded that higher microbiome α diversity, along with more butyrate-producing gut bacteria, was associated with less T2D and with lower insulin resistance among individuals without diabetes. These findings could help provide insight into the etiology, pathogenesis, and treatment of T2D. The study was published on July 29, 2021 in the journal JAMA Network Open.
Related Links:
Erasmus University Medical Center
Diasorin
Illumina
Abbott Laboratories
Differences in gut microbiome composition with T2D status may comprise pathways on how dietary and other environmental factors affect development of insulin resistance and T2D. Patients with T2D have a lower overall α diversity of gut microbiome composition than healthy people.
A multidisciplinary international team of scientists led by those at the Erasmus University Medical Center (Rotterdam, the Netherlands) examined associations of gut microbiome composition with insulin resistance and T2D in a large population-based setting controlling for various sociodemographic and lifestyle factors. The team carried out a cross-sectional analysis included 2,166 participants from two Dutch population-based prospective cohorts.
The investigators used an automated stool DNA isolation kit (Diasorin, Saluggia, Italy) to isolate bacterial DNA. The V3 and V4 hypervariable regions of the bacterial 16S ribosomal RNA gene were amplified and sequenced on the MiSeq platform (Illumina, San Diego, CA, USA). Serum insulin was measured by electrochemiluminescence immunoassay technology. In one study, glucose levels were measured by hydrogen 1 nuclear magnetic resonance, and serum insulin was measured on an architect system (Abbott Laboratories, Lake Forest, IL, USA). Associations among α diversity, β diversity, and taxa with the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and with type 2 diabetes were examined.
The investigators reported that lower microbiome Shannon index and richness were associated with higher HOMA-IR (e.g., Shannon index, −0.06; 95% CI, −0.10 to −0.02), and patients with type 2 diabetes had a lower richness than participants without diabetes (odds ratio [OR], 0.93; 95% CI, 0.88-0.99). The β diversity)was associated with insulin resistance. A total of 12 groups of bacteria were associated with HOMA-IR or type 2 diabetes. There were five taxa whose higher abundance was tied to lower prevalence of T2D:Clostridiaceae 1, Peptostreptococcaceae, Clostridium sensu stricto 1, Intestinibacter, and Romboutsia. There were seven taxa whose greater abundance was associated with lower HOMA-IR including Christensenellaceae and Marvinbryantia.
The authors concluded that higher microbiome α diversity, along with more butyrate-producing gut bacteria, was associated with less T2D and with lower insulin resistance among individuals without diabetes. These findings could help provide insight into the etiology, pathogenesis, and treatment of T2D. The study was published on July 29, 2021 in the journal JAMA Network Open.
Related Links:
Erasmus University Medical Center
Diasorin
Illumina
Abbott Laboratories
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans